OncoTherapy Science, Inc. (TSE: 4564)
Health Care · Biotechnology · JP
¥18.00
-5.26% today · -21.7% 1Y
OncoTherapy Science, Inc. (TSE: 4564) operates in the Biotechnology industry within the Health Care sector. The company is valued at $46.54M and employs 46 people.
Over the last twelve months the share price has lost 21.7%, trading between 18.00 and 34.00.
Tweenvest scores OncoTherapy Science, Inc. across four factors: quality 37/100, value 50/100, growth 60/100. Its strongest factor is growth.
4564 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $46.54M
- Revenue (TTM)
- $4.78M
- P/E
- —
- EPS
- -2.47
- Dividend yield
- —
- Beta (5Y)
- 0.30
- 52-week high
- ¥34.00
- 52-week low
- ¥18.00
- Avg volume (3M)
- —
- Shares outstanding
- 408.24M
- Employees
- 46
- Next earnings
- —
About OncoTherapy Science, Inc.
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
- ISIN
- JP3202150003
- Founded
- 2001
- Listed since
- Sep 29, 2005
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Norda ASAOTCNO: NORD | $47.08M | Nkr86.00 | — |
| TaiRx, Inc.TPEX: 6580 | $46.82M | NT$13.55 | -6.87% |
| Cytogen, Inc.KOSDAQ: A217330 | $46.75M | ₩2,695.00 | -7.86% |
| Solasia Pharma K.K.TSE: 4597 | $46.69M | ¥27.00 | -6.90% |
| Apollomics, Inc.NasdaqCM: APLM | $46.34M | $21.10 | -1.86% |
| Prescient Therapeutics LimitedASX: PTX | $46.16M | AU$0.06 | -12.12% |
| ImageneBio, Inc.NasdaqCM: IMA | $45.86M | $4.04 | -4.72% |
| Harvard Apparatus Regenerative Technology Inc.OTCPK: HRGN | $45.23M | $2.23 | -3.04% |
Figures last refreshed Oct 18, 2026.